Progress in Medicinal Chemistry
- 1st Edition, Volume 46 - April 2, 2008
- Editors: G. Lawton, David R. Witty
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 4 - 5 3 0 1 8 - 9
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 5 6 9 6 8 - 0
Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the many advances in genetics,… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote*Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry
*Available as an online resource via ScienceDirect
* 11-beta-Hydroxysteroid dehydrogenase (new approach to glucocorticoid regulation)
* Nicotinic a7 choline receptor (agonists and positive allosteric modulators)
* Bradykinin receptor (new approach to pain therapy)
* Histone deacetylase (new drugs for cancer)
* 5-HT2c receptor modulators (various CNS indications)
- No. of pages: 420
- Language: English
- Edition: 1
- Volume: 46
- Published: April 2, 2008
- Imprint: Elsevier Science
- Hardback ISBN: 9780444530189
- eBook ISBN: 9780080569680
GL
G. Lawton
From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines.
Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities.
Geoff serves on the Board of Antabio, a French biotech company developing tomorrow’s antibacterial drugs.
He is a founder of INMedD, a new medicines discovery social enterprise.
DW
David R. Witty
In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.
David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.
Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.